Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
Neurology: Clinical Practice · Vol. 13 Published January 1, 2023
More on these topics
Browse all publications →-
2025 · CNS Drugs
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
-
2025 · Alzheimer's & Dementia
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer’s disease
-
2025 · Journal of Alzheimer’s Disease
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial
-
2025 · J Prev Alzheimers Dis
Donanemab: Appropriate use recommendations